Feb 24th 2012 - Edison Investment Research today published a report on Vernalis (VER.L, LSE:VER, LON:VER) entitled "Worth The Wait". In summary, the report says:
Vernalis’s proposed £65.9m equity raise (net of costs) and multi-product in-licensing deal with private US company Tris Pharma are the latest steps in its business transformation strategy. While the company has made progress in its clinical pipeline and in balancing investment in research, pipeline expansion through M&A was always the most important facet of its three-part strategy to become a diversified, profitable and sustainable specialty pharma company. The scope of the Tris deal and the size of the addressable market means that Vernalis is a step closer to this goal.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »